Precision oncology in sarcomas: Divide and conquer

Roberto Carmagnani Pestana, Roman Groisberg, Jason Roszik, Vivek Subbiah

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Sarcomas are a heterogeneous group of rare malignancies that exhibit remarkable heterogeneity, with more than 50 subtypes recognized. Advances in next-generation sequencing technology have resulted in the discovery of genetic events in these mesenchymal tumors, which in addition to enhancing understanding of the biology, have opened up avenues for molecularly targeted therapy and immunotherapy. This review focuses on how incorporation of next-generation sequencing has affected drug development in sarcomas and strategies for optimizing precision oncology for these rare cancers. In a significant percentage of soft tissue sarcomas, which represent up to 40% of all sarcomas, specific driver molecular abnormalities have been identified. The challenge to evaluate these mutations across rare cancer subtypes requires the careful characterization of these genetic alterations to further define compelling drivers with therapeutic implications. Novel models of clinical trial design also are needed. This shift would entail sustained efforts by the sarcoma community to move from one-size-fits-all trials, in which all sarcomas are treated similarly, to divide-and-conquer subtype-specific strategies.

Original languageEnglish (US)
JournalJCO Precision Oncology
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Precision oncology in sarcomas: Divide and conquer'. Together they form a unique fingerprint.

Cite this